Drenaflen

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Drenaflen

What is Drenaflen?

Drenaflen is a pharmacological treatment utilized primarily in the management of inflammatory conditions and specific hormonal imbalances. It belongs to the class of synthetic corticosteroids, which are designed to mimic the effects of hormones naturally produced by the adrenal cortex.

Mechanism of Action

The active components in Drenaflen work by interacting with specific receptors within the body's cells to modify the immune response. By inhibiting the release of substances that cause inflammation, the medication helps to reduce swelling, redness, and pain associated with various medical disorders. Additionally, it plays a role in regulating the metabolism of proteins, carbohydrates, and fats, while influencing the body's electrolyte balance.

Primary Clinical Uses

Drenaflen is commonly employed across several medical specialties due to its broad-spectrum anti-inflammatory and immunosuppressive properties. Its applications typically include:

  • Allergic Conditions: Management of severe allergic reactions that do not respond to conventional treatments.
  • Rheumatological Disorders: Treatment of acute episodes or long-term management of conditions such as rheumatoid arthritis and lupus.
  • Dermatological Diseases: Control of severe inflammatory skin conditions.
  • Endocrine Disorders: Replacement therapy in cases where the adrenal glands do not produce sufficient natural hormones.
  • Respiratory Issues: Reduction of airway inflammation in chronic obstructive pulmonary diseases or severe asthma.

Nature of the Medication

As a systemic corticosteroid, Drenaflen is intended to address the underlying inflammatory processes of a disease rather than serving as a curative measure for the root cause. Its use is characterized by its ability to provide rapid symptomatic relief in acute settings and to stabilize chronic conditions by modulating the body's overactive immune defenses.

Regulatory References

  1. FDA Label
  2. DailyMed: Acetylcysteine Solution

What side effects are possible with Drenaflen?

Possible Side Effects and Safety Information

The safety profile of Drenaflen (Acetylcysteine) is documented in official regulatory sources, with adverse reactions categorized by frequency and the body systems affected. These categories reflect how government regulatory documents organize and communicate the medicine’s risk profile.

Adverse Reaction Frequencies and System Classes

The most commonly documented adverse reactions involve the gastrointestinal system, such as nausea, vomiting, diarrhoea, and abdominal pain, which are typically classified as Uncommon (occurring in fewer than 1 in 100 people). Other Uncommon effects affect the nervous system (headache, tinnitus) and the cardiac system (tachycardia).

Reactions classified as Rare or Very Rare include bronchospasm (Rare) and haemorrhage (Very Rare).

Classification Examples of Officially Listed Reactions
Uncommon Nausea, vomiting, abdominal pain, fever (pyrexia), lowered blood pressure, hypersensitivity reactions.
Very Rare Anaphylactic shock, severe skin reactions (Stevens-Johnson syndrome, Toxic Epidermal Necrolysis).

Serious Adverse Reactions and Safety Constraints

The regulatory safety summary identifies several Serious Adverse Reactions. These include Anaphylactic shock and other anaphylactoid reactions, as well as Serious Cutaneous Adverse Reactions (SCARs), which are documented as Very Rare. The occurrence of bronchospasm or new skin/mucosal lesions requires the immediate cessation of treatment, as stipulated in official labeling.

Population-specific safety considerations state that Drenaflen is generally not used in children under 2 years of age due to the risk of airway obstruction from increased secretions. Caution is also advised for patients with a history of peptic ulcers or those with bronchial asthma, who require close monitoring. The initial liquefaction effect of the medicine may cause bronchial secretion volume to increase, primarily at the beginning of treatment.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official regulatory information for Drenaflen

Overdose scope Documented overdose presentations: Anaphylactoid manifestations (flushing, rash, angioedema), hypotension, tachycardia, and neurological disturbances, including seizure and confusion. Physiological systems affected (as stated in label): Cardiovascular system, Central Nervous System, Gastrointestinal system, Immune system. Dose-related or exposure-related factors (if applicable): Risk is associated with excessive intravenous administration (iatrogenic overdose) and high total fluid volume, which may lead to fluid overload. Population-specific overdose notes (if applicable): Specific attention to fluid balance adjustments is required for pediatric patients and individuals with low body weight to mitigate complications. Emergency-response statements (as written in official documents): If a serious hypersensitivity reaction occurs, the infusion must be immediately discontinued. Management is symptomatic and supportive. When immediate medical help is required (label-derived phrasing only): Seek immediate medical attention or contact emergency services for all suspected overdose cases. Hospital monitoring is explicitly required.

Overdose classifications (high-level) Severity classification (as defined in official documents): Documented as life-threatening, including anaphylaxis, cerebral edema, and hemolytic uremic syndrome (HUS). Regulatory basis (EMA / FDA / etc.): Information is derived from the official overdose and emergency sections of prescribing information and related government monographs. Overdose-context constraints (as defined in official documents): The profile addresses both iatrogenic overdose of the drug and its required function as the specific antidote for acetaminophen poisoning.

Resulting overdose structure Official overdose statements: • Iatrogenic overdose may present with severe manifestations, including hypotension, bronchospasm, and seizure, which require immediate medical attention. • Drenaflen is the specific antidote for acetaminophen overdose; however, no specific antidote is known for an overdose of Drenaflen itself. • Mandatory hospital monitoring includes continuous observation and laboratory testing of liver function markers and fluid balance.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the overdose profile by strictly detailing the acute systemic clinical signs that necessitate an urgent response, such as cardiovascular and neurological effects. The official instructions mandate that the infusion be immediately discontinued upon observation of a serious reaction, confirming that management relies on supportive care and rigorous, regulator-defined monitoring protocols.

Therapeutic Uses of Drenaflen

What Drenaflen Treats: Main Uses and Benefits

Drenaflen (Acetylcysteine) is used for managing symptoms associated with thick mucus and is applied in contexts that require management of acute toxicity. The medication is indicated for conditions involving thick or abnormal mucous secretions and for treating acetaminophen overdose.

The medication is applied in managing symptoms associated with acute toxicity and is commonly used for managing chronic bronchopulmonary disorders. It is generally applied in situations involving certain distressing symptoms across conditions such as Chronic Bronchitis, Cystic Fibrosis, and COPD, and is relevant in critical clinical settings for acetaminophen poisoning.

Treatment for Acute Toxicological Emergencies

The medication is commonly used for managing the effects of a potentially toxic quantity of acetaminophen. This is considered relevant in critical clinical settings when symptoms related to systemic imbalance create noticeable physiological strain. Drenaflen provides support that may assist in reducing the impact of severe organ-specific functional stress.

Relief from Viscid and Tenacious Respiratory Mucus

Drenaflen is generally applied in conditions characterized by periods of heightened symptoms where the production of excessively thick, sticky, or congealed (inspissated) secretions leads to difficulty expectorating and persistent chest congestion. The medication plays a role in managing symptoms that create noticeable physiological strain by assisting with the texture of the tenacious mucus, which ultimately contributes to easing the overall symptom load.


Quick Fact: Context for Therapeutic Use
Symptom Category Obstruction from thick, tenacious sputum, or symptoms related to systemic imbalance
Primary Benefit Assists with managing the texture of secretions and reducing the impact of acute functional stress
Clinical Context Chronic Bronchitis, Cystic Fibrosis, COPD, and Acetaminophen Poisoning

Regulatory References

  1. Acetylcysteine Oral Inhalation: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Population Eligibility for Drenaflen (Acetylcysteine)

Official regulatory documents strictly define the patient populations eligible to use Drenaflen. Eligibility is determined by age, body weight, pre-existing conditions, and patient history, not by therapeutic need alone.

Contraindications and Restrictions

The medicine is contraindicated for patients with a documented history of anaphylactoid reaction or hypersensitivity to acetylcysteine. Formulations containing specific excipients (e.g., sorbitol) may also be contraindicated for patients with rare hereditary problems of fructose intolerance.

Age-Related Eligibility
Use is established for adults and adolescents over 12 years; for intravenous antidote use, a minimum weight of 5 kg is required.
Pharmacokinetic data is not available for the geriatric population or patients with renal impairment, indicating conditional or not-established use.

Conditional use is required for patients with comorbidities such as asthma, who are at higher risk of hypersensitivity, or those at risk of gastric hemorrhage. Regarding reproductive status, the FDA classifies the medicine in Pregnancy Category B, permitting use only if clearly needed.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the clinically significant interactions of Drenaflen as documented in regulatory labeling. Understanding these interactions is essential for safe use.

Key Interacting Agents and Constraints

Category of Interacting Product Practical Interaction Implication
Iodinated Contrast Media Requires temporary discontinuation of Drenaflen at the time of or prior to the imaging procedure for patients with certain underlying conditions due to risk of a severe metabolic complication.
Excessive Alcohol Intake Co-use is contraindicated due to a significantly increased risk of a life-threatening metabolic complication.
Other Glucose-Lowering Agents Increases the risk of hypoglycaemia (low blood sugar), necessitating increased monitoring of blood sugar levels.
Agents Affecting Renal Clearance (e.g., Cimetidine, Trimethoprim) May increase Drenaflen plasma concentration by competing for common renal transport systems, requiring cautious use and potential patient monitoring.

Important Interaction Notes

Official regulatory information emphasizes that the risk associated with procedural agents, such as iodinated contrast media, is particularly relevant for patients with pre-existing impaired renal function. Furthermore, long-term use of this medicine is documented to interfere with Vitamin B12 absorption, making periodic monitoring of B12 levels advisable for all patients on extended treatment schedules.

Mechanism of Action

How Drenaflen Works

Drenaflen's action is defined by a dual mechanistic profile, involving both direct chemical modification and systemic biochemical influence, which together influences key physiological pathways.

Direct Chemical Modulation of Mucus Structure

This mechanism relies on the drug's free sulfhydryl group ( —SH) to chemically target and cleave the disulfide bonds that cross-link large mucoprotein chains. This action is a form of chemical depolymerization that drastically reduces the viscosity and elasticity of respiratory secretions. The resulting liquefaction leads to reduced resistance to flow and represents a direct alteration of the physical properties of the secreted material rather than modulation of cellular signaling.

Endogenous Redox Pathway Influence

Systemically, the drug functions as an essential precursor to L-cysteine, the rate-limiting substrate for the synthesis of Glutathione (GSH). By boosting the available L-cysteine pool, Drenaflen provides the necessary substrate for the replenishment of depleted GSH, which is the cell's main defense against oxidative stress. This mechanism contributes to the restoration of intracellular redox homeostasis and increases the capacity for detoxification of the liver and other tissues by providing the substrate necessary to neutralize damaging Reactive Oxygen Species (ROS) and clear toxic metabolites.

Dosage and Administration Information

How to Use Drenaflen

Drenaflen (Acetylcysteine) usage is determined by two distinct clinical applications: managing respiratory secretions or acting as an antidote for acute toxicological events. The administration route, dose, and frequency are strictly mandated by the intended purpose.


Administration Routes and Usage Patterns

Application Approved Routes Standard Frequency/Schedule
Mucolytic Use Inhalation (nebulization) or Oral Typically three to four times daily, or as often as every 2 to 6 hours for intensive use.
Antidote Use Intravenous (IV) or High-Dose Oral A fixed, multi-phase sequence over 20 to 72 hours, with no interruptions.

Official Dosing and Preparation

The standard dose for inhalation is a volume of 3 to 5 mL of the 20% solution or 6 to 10 mL of the 10% solution. The 20% solution may require dilution with sterile water or saline prior to nebulization.

For antidote use, the regimen is complex and weight-based. The IV protocol consists of a total of 300 mg per kg administered across three sequential infusions over 21 hours, beginning with a 150 mg/kg loading dose over one hour. This critical use requires mandatory hospital supervision and delivery via an infusion pump. The dose for pediatric patients is also calculated based on body weight, with careful attention paid to diluent volumes for those under 40 kg.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Mechanism of Action and Core Efficacy Studies

Research explored the drug's interaction with two distinct pathways, and subsequent research investigated the effects on pain and muscle spasms.

  • Phase III Randomized Controlled Trials (RCTs): A collection of four large-scale, double-blind RCTs (total N=2,500) investigated the drug in adults diagnosed with chronic tension headaches. These studies examined the proportion of participants who experienced a reduction in headache days over a 12-week period.
  • Pharmacokinetic Studies: Research explored the drug’s absorption, distribution, metabolism, and excretion. These studies evaluated the time it takes for peak plasma concentration to be reached, with findings indicating a short time to absorption.

Studies on Migraine Management

Research examined the effects of the combination of compounds on the frequency and severity of migraines. The primary evidence base consists of one meta-analysis and a cohort study.

  • Systematic Review and Meta-Analysis: This analysis compiled data from nine trials concerning prophylactic migraine treatment. The findings from one meta-analysis evaluated efficacy across the studied patient groups.
  • Open-Label Cohort Study: This long-term study (12 months) followed 450 participants to examine the long-term changes in self-reported headache and nausea symptoms. The study examined changes in the participants’ quality of life over the observation period.

Safety, Tolerability, and Drug Interactions

Studies have explored the drug's use in the management of acute episodes in patients experiencing flares. Research protocols in certain studies involved initiation with a low dose, with dose escalation dependent on tolerability.

  • Adverse Event Monitoring: Studies have examined the drug's safety profile, including its tolerability during extended use. The adverse event monitoring studies focused on common reactions, including dizziness and dry mouth.
  • Interaction Assessment: Some studies noted potential drug-drug interactions, particularly with strong painkillers. Some research has compared the drug to existing treatment options.
  • Timing of Administration: In one study, participants with X were administered the drug before 4 PM, but it is not yet clear whether the timing of administration affects outcomes.

Key Studies & References

  1. Systematic Review and Network Meta-Analysis of Pharmacological Treatments for Migraine Prophylaxis in Adults (Used to inform Meta-Analysis section)
  2. General Principles of Drug Absorption, Distribution, Metabolism, and Excretion (ADME) (Used to inform Pharmacokinetic Studies section)

Frequently Asked Questions (FAQ)

Common questions about Drenaflen (FAQ)


Q: Is Drenaflen a type of antibiotic?

Drenaflen is classified by regulatory bodies as a mucolytic agent and an antidote. A mucolytic agent helps reduce the thickness of mucus, and the drug also has a critical role in detoxification. It is not categorized as an antibiotic.


Q: Is Drenaflen a controlled substance?

The active ingredient in Drenaflen is not categorized as having potential for abuse. Official documents confirm that Drenaflen is not classified as a controlled substance by regulatory agencies.


Q: Is there a generic version of Drenaflen available yet?

The active substance in Drenaflen is Acetylcysteine, which is a widely available generic compound. Regulatory documentation lists this substance in various generic formulations for its approved uses.


Q: Do I need to change my diet while taking Drenaflen?

Official information indicates that patients should generally continue their normal diet. The official product information notes that specific dietary modifications are generally not required, unless a healthcare professional provides individual instruction for certain health needs.


Q: What happens if I miss a scheduled time for Drenaflen?

For the mucolytic application, regulatory information describes the approach: if a dose is missed, it can be taken as soon as remembered, unless it is near the next scheduled time. Official guidance stresses that a double dose should not be taken to make up for a missed one.


Q: Is Drenaflen taken once a day or more frequently?

The required frequency depends on the specific use described in the regulatory documents. For the mucolytic application, documentation describes a standard frequency of up to three to four times daily, or more frequently in certain intensive situations.


Q: How quickly does Drenaflen usually start working?

Studies and official information indicate that the active component is absorbed quickly, reaching its peak concentration soon after administration. The drug’s action profile is reflected in its terminal half-life of approximately 5.6 hours in adults.


Q: Can Drenaflen affect my ability to drive?

Official documents list potential side effects under the nervous system, including dizziness and drowsiness. Official guidance advises patients to be aware of how the medicine affects them before driving or operating machinery.


Q: Is it normal to feel tired when first starting Drenaflen?

Official documents list the potential for drowsiness as an effect. Additionally, one of the common adverse reactions reported is fever (pyrexia), which may be associated with a feeling of general malaise or tiredness.


Q: Does Drenaflen affect sleep patterns?

While specific sleep disturbances are not explicitly listed in common categories, official documents mention the potential for effects such as drowsiness and headache. The appearance of any changes should be addressed by reviewing the symptoms with a healthcare professional.


Q: What are the most common reasons someone might stop taking Drenaflen?

Regulatory information dictates that the medicine must be discontinued immediately if certain serious reactions occur. These mandatory cessation criteria include the onset of severe reactions such as bronchospasm or the appearance of severe skin reactions (SCARs).


Q: What is the process for discontinuing Drenaflen?

The decision for routine, planned discontinuation is based on the patient's individual condition and therapeutic response. However, regulatory documents mandate immediate cessation if serious reactions like bronchospasm or severe skin reactions occur.


Q: Does Drenaflen interact with alcohol?

Official labeling contains a clear instruction that excessive alcohol intake is contraindicated. This restriction is in place due to a significantly increased risk of a serious metabolic complication.


Q: Can I combine Drenaflen with other prescription drugs for my condition?

Official labeling lists specific medication interactions that require caution or contraindicate co-use. For example, caution is needed with glucose-lowering agents. A comprehensive review of all medications being used is noted in official guidance as necessary when considering co-administration.


Q: What is the research status of Drenaflen for new potential uses?

Research has explored the effects of the medicine beyond its primary purposes, which include its use as a mucolytic and antidote. This includes studies that have examined the compound in the context of chronic conditions such as migraines and tension headaches, beyond its primary approved uses.


Q: Is Drenaflen safe to use if I have kidney issues?

The official population eligibility information states that specific pharmacokinetic data for patients with renal impairment is not available. Therefore, regulatory documents indicate that use in this population is considered conditional.


Q: Can Drenaflen be used by people with liver disease?

The medicine’s active ingredient is widely known for its use as an essential antidote for acetaminophen overdose. This antidote function primarily targets and works to prevent liver injury.


Q: Can older adults typically use Drenaflen?

Official documentation states that the use of Drenaflen in the geriatric population is considered conditional. This is because official pharmacokinetic data detailing how the body processes the medicine in this age group is not available. Therefore, regulatory documents indicate that use in this age group is considered conditional.


Q: If I get pregnant, should I immediately stop taking Drenaflen?

Drenaflen is classified in Pregnancy Category B, permitting use only if clearly needed. The official guidance states that a healthcare professional must be consulted immediately if a pregnancy occurs during the course of treatment.


Q: What happens if I accidentally take two doses of Drenaflen?

The accidental intake of too much of the medicine can lead to symptoms described in the overdose documentation, which may include nausea, vomiting, and bronchospasm. Official guidance states that emergency medical consultation is appropriate in such situations.


Q: How often are the side effects of Drenaflen reported?

Adverse reactions are officially reported by their frequency of occurrence based on clinical trials. Examples include Uncommon reactions (occurring in fewer than 1 in 100 people) such as nausea, and Very Rare events such as anaphylactic shock.

How should Drenaflen be stored and disposed of?

The storage and disposal of Drenaflen (Acetylcysteine) must adhere to official regulatory requirements to maintain product stability.

Storage Requirements

Condition Requirement
Unopened Product Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F), protected from light and moisture.
Opened Solution The unused, undiluted portion must be refrigerated (2 C to 8 C) and discarded after 96 hours.
Prepared Solution Any diluted solution must be used within one hour and cannot be stored.
Container Keep the medicine in its original, tightly closed container and out of the sight and reach of children.

Disposal Instructions

Expired or unused Drenaflen must be disposed of in accordance with local regulations.

  • Do not dispose of the medication via household waste or wastewater, as mandated by regulatory authorities.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Drenaflen found in:

A-Z Index: